AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03149783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine HCL
Description: Ropivacaine injected after placement of catheters, then infused during the operation
Study NCT03149783 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride
Description: Placebo
Study NCT03633383 — intervention group
Intervention type: DEVICE
Intervention: Transcatheter aortic valve
Description: Self-expandable aortic valve prothesis
Study NCT01217112 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mg capsules, QDS, PO, 91 days
Study NCT04231526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 2 cycles of neoadjuvant pembrolizumab (200mg IV every 21 days)
Study NCT04231526 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Standard of care surgery
Study NCT04231526 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Standard of care surgery
Study NCT02892955 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartMate 3 LVAS
Description: Implantation of HeartMate 3 LVAD to evaluate safety and clinical performance of the HM3 LVAS for the treatment of advanced, refractory, left ventricular heart failure following completion of enrollment in the MOMENTUM 3 IDE Study.
Study NCT04044989 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser
Description: Diode laser device was used for photobiomodulation
Study NCT04044989 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: light-emitting diode (LED)
Description: LED device was used for photobiomodulation
Study NCT04044989 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Diode laser device was used for placebo effect
Study NCT02637882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ear plug
Description: The patients will receive the first intervention (ear plug) in the third night (N3) from 9 pm to 6 am.and the patient will complete the sleep questionnaire sheet and delirium scale.
Study NCT02637882 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Eye mask
Description: The patients will receive the second intervention (eye mask) in the second night (N2) from 9 pm to 6 am.and the patient will complete the sleep questionnaire sheet and delirium scale
Study NCT02637882 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mixed intervention (ear plug and eye mask)
Description: The patients will receive the intervention (eye mask and ear plug) in the first night (N1) from 9 pm to 6 am.and the patient will complete the sleep questionnaire sheet and delirium scale
Study NCT04026490 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate Intervention
Description: The Interventionist will use motivational interviewing skills, assess ethnic and racial microaggressions, and provide support, screen for posttraumatic stress, and, if appropriate, link student to advanced care. The student may meet with the Interventionist several times during the remainder of the school year. These meetings will be approximately 10-30 minutes in length and occur during the school day in a private location determined by the Interventionist. The student may be referred to additional resources as a result of the meetings. The meetings will be documented by the Interventionist using a case management system (in RedCap).
Study NCT04026490 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist Intervention
Description: In order to compare outcomes contemporaneously, students from waitlisted schools will be asked to complete baseline and follow-up surveys, which will be collected at approximately the same time as in the immediate intervention schools. The data will be captured for analysis at the end of the study. Students will complete intervention following the waitlist period.
Study NCT01994148 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Description: In this study, laparoscopic intervention will be performed under carbon dioxide pneumoperitoneum (pressure, 10-12 mm Hg; flow volume, 8-10 L/min). A 12-mm trocar will be placed in the umbilicus with use of an open technique and to establish pneumoperitoneum.A 10-mm and a 5-mm trocar will be inserted in the right and left flanks,respectively.
Study NCT03725488 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: students were involved in the pre-clinical prosthodontic lab. Participation in these labs were mandatory and it involved crown and bridge preparations on typodont models. There were 2 sessions of these labs per week, one for each gender. Each session lasted for 3 hours.~The study was conducted in 2 phases. At the beginning of the first phase of the study, the labs were conducted without any BM for 4 weeks. PSS(perceived stress scale), a standardized and validated, self-reporting international test was used for measuring the level of psychological stress were administered to all participants.
Study NCT02626026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirabrutinib
Description: Capsules administered orally.
Study NCT02626026 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules administered orally.
Study NCT02182193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120 capsules charge 1
Study NCT02182193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120 capsules charge 2
Study NCT02182193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIBF 1120 drinking solution
Study NCT00299234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: titration schedule: 0.5 to 1.5 mg/kg/day
Study NCT00299234 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atomoxetine
Description: titration schedule: 0.5 to 1.5 mg/kg/day
Study NCT02763384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-8040
Study NCT02763384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelarabine
Study NCT02693873 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: GLA:D Canada (education and neuromuscular exercise program)
Description: EDUCATION: 2 sessions cover OA topics (e.g. diagnosis, causes, risk factors, symptoms, treatment). Education also aims to strengthen beliefs in the value of exercise to control and improve pain and encourage exercise adherence after the program.~EXERCISE: 12 sessions (twice weekly, each about 1-hour) are supervised by therapist(s) with individual progression of exercises when good neuromuscular functioning is demonstrated. Exercises are performed using both legs and focus on sensorimotor control, functional stability, and muscular strength. Exercises involve a 10-minute cycle warm-up followed by a 4-station circuit (i.e. 2 exercises per station with 3 progressive levels of difficulty performed in 2 to 3 sets with 10 to 15 repetitions).
Study NCT01028573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-ELS (Golytely)
Description: 4L consumed evening before colonoscopy
Study NCT01028573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-ELS (Golytely)
Description: 2L consumed on the evening before and 2L consumed on the morning of Colonoscopy
Study NCT01028573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miralax mixed with Gatorade
Description: 238g of PEG-3350 (Miralax) mixed with 2L of Gatorade consumed on the evening before colonoscopy
Study NCT01028573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miralax
Description: 1L of PEG-3350 + Gatorade consumed on the evening before and 1L of PEG-3350 + Gatorade consumed on the morning of Colonoscopy
Study NCT01735123 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary intervention
Description: hydrolyzed vs. nonhydrolyzed infant formula
Study NCT01640756 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AqueSys Microfistula Implant
Description: Placement of the AqueSys Microfistula Implant in the study eye
Study NCT03614923 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Etokimab
Description: Administered by subcutaneous injection
Study NCT04358445 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnesium-Rich Artificial Cerebrospinal Fluid
Description: The Magnesium-Rich Artificial Cerebrospinal Fluid (MACSF) is composed of several qualified clinical intravenous injections according to a specific formula, which has similar physical and chemical properties to physiological CSF. MACSF will be freshly made and used. It will be prepared by trained professionals on a specific workbench and sent to the operating room in a special container. Finally, it will be used in the operation by the neurosurgeons. Aseptic principles should be enforced strictly during the whole procedures, including preparation, transportation and application.
Study NCT00724347 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consonant Identification Training
Description: Subjects received psychophysically adaptive, consonant identification training in consonant discrimination on PCs in their homes.
Study NCT01176903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Description: pressurized metered dose inhaler
Study NCT01176903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: inhalation powder, hard capsule
Study NCT01176903 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: pressurized metered dose inhaler
Study NCT00889213 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Falciform patch and fibrin glue application
Description: Following standard surgical exploration, the pancreatic gland will be mobilized appropriately to the level of transaction in the pancreatic neck, body or tail. The gland may be divided by stapling device, electrocautery or sharp division. Suture material will be at the discretion of the surgeon but may include absorbable or non-absorbable braided on mono-filament. Those patients randomized to autologous falciform patch will have the falciform membrane harvested. The falciform patch will be laid over the suture line of the resected pancreatic stump and secured to the pancreatic capsule utilizing #4-0 PDS suture placed at 12, 3, 6, and 9 o'clock positions. Fibrin glue (Vitagel) will be utilized to fill the potential space within this membranous capsule. Fibrin glue will be prepared as per standard instructions. Drains will be placed in the splenic bed and/or adjacent to the stump of the pancreas for postoperative fluid evacuation.
Study NCT00889213 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard pancreatic closure
Description: Following standard surgical exploration, the pancreatic gland will be mobilized appropriately to the level of transaction in the pancreatic neck, body or tail. The gland may be divided by stapling device, electrocautery or sharp division. Suture material will be at the discretion of the surgeon but may include absorbable or non-absorbable braided on mono-filament.
Study NCT03266250 — intervention group
Intervention type: PROCEDURE
Intervention: spinal anesthesia
Description: Transthoracic echocardiography of inferior vena cava before spinal anesthesia
Study NCT00290823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: 400 mg tablet taken orally twice daily
Study NCT00290823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 6mg or 8mg taken daily
Study NCT00290823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: 20 mg tablet taken orally daily
Study NCT02979535 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYD Dengue Vaccine
Description: 0.5 mL, SC at Day 0, Months 6 and 12
Study NCT02979535 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYD Dengue Vaccine
Description: 0.5 mL, SC at Months 1, 7, and 13
Study NCT02979535 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant
Description: 0.5 mL, IM at Day 0 and Month 6
Study NCT00505739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: 200 mg by mouth (PO) Daily x 4 Weeks
Study NCT02588391 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Training (Active)
Description: Online computer games targeting attention, EF, and problem-solving match the child's skill level.
Study NCT02588391 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Training (Passive)
Description: Online computer games targeting attention, EF, and problem solving are set to a consistent level.
Study NCT02588391 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brain Training (Active or Passive)
Description: Online computer games targeting attention, EF, and problem-solving either match the child's level or are set to a consistent level depending on which version the child has already completed.
Study NCT00748046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 chloride (BAY88-8223)
Description: The required volume of study drug to be administered to a patient was calculated using the patient's body weight.
Study NCT04763122 — intervention group
Intervention type: OTHER
Intervention: not applicable as it is a retrospective study
Description: It is a retrospective study
Study NCT02662842 — intervention group
Intervention type: DEVICE
Intervention: FlowSmart Infusion Set
Description: Use of set for subcutaneous insulin infusion, with set change every three days.
Study NCT02662842 — intervention group
Intervention type: DEVICE
Intervention: Current Infusion Set
Description: Use of set for subcutaneous insulin infusion, with set change every three days.
Study NCT04482751 — intervention group
Intervention type: DRUG
Intervention: Corifollitropin alfa
Description: AMH will be measured during ovarian stimulation with corifollitropin alfa
Study NCT04413890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dinoprostone vaginal gel
Description: Prostaglandin gel 0.5, 1 or 2 mg
Study NCT04413890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone vaginal gel
Description: Prostaglandin gel 0.5, 1 or 2 mg
Study NCT01669122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine
Description: 4 mg nicotine lozenge experimental
Study NCT03614923 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered by subcutaneous injection
Study NCT03614923 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection
Study NCT03614923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate Nasal Spray
Description: Mometasone Furoate Nasal Spray (MFNS) was used from 4 weeks prior to Day 1 (Run-in period) through the end of the study. Participants used 2 actuations (50 μg/actuation) in each nostril BID, total daily dose of 400 μg. Participants intolerant to BID intranasal corticosteroids (INCS) could use the lower dose regimen of 1 actuation in each nostril BID, total daily dose of 200 μg.
Study NCT03614923 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mometasone Furoate Nasal Spray
Description: Mometasone Furoate Nasal Spray (MFNS) was used from 4 weeks prior to Day 1 (Run-in period) through the end of the study. Participants used 2 actuations (50 μg/actuation) in each nostril BID, total daily dose of 400 μg. Participants intolerant to BID intranasal corticosteroids (INCS) could use the lower dose regimen of 1 actuation in each nostril BID, total daily dose of 200 μg.
Study NCT04457245 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo whole body PET/CT
Study NCT04457245 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluorine F 18 DCFPyL
Description: Given IV
Study NCT04457245 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo whole body PET/CT
Study NCT04457245 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo standard of care definitive radiation therapy
Study NCT04457245 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo standard of care definitive radiation therapy
Study NCT01545271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: xenon gas
Description: Inhalation via endotracheal tube of 50% xenon for 18 hours, including during transport for outborn babies, starting within 5 hours after birth.
Study NCT01545271 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole body cooling
Description: Cooling of baby to reduce rectal temperature to 33.5 degree Centigrade(standard treatment), including during transport for outborn babies, starting within 3 hours after birth.
Study NCT01545271 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Whole body cooling
Description: Cooling of baby to reduce rectal temperature to 33.5 degree Centigrade(standard treatment), including during transport for outborn babies, starting within 3 hours after birth.
Study NCT00082784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV
Study NCT00082784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvocidib Hydrochloride
Description: Given IV
Study NCT00082784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03606759 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Weekly assessment
Description: Weekly assessment during 3 months :~Severity of addiction (Addiction Severity Index, ASI) Mini International Neuropsychiatric Interview, MINI Craving intensity (BILAN-7 jours) Individual cues of each participant (QSA) Substance use and gambling (BILAN-7 jours)
Study NCT02725671 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Explorer
Description: ECG device which records comprehensive voltage potential data in the myocardium
Study NCT03473834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified exercise programme
Description: The exercise will be modified from the standardized exercise program (Schenkman, 1998) includes a series of exercises based on the concept that muscle length and coordination.
Study NCT03473834 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication
Description: The control group will be received the normal medication from their doctor.
Study NCT03473834 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medication
Description: The control group will be received the normal medication from their doctor.
Study NCT01965535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV/SOF (90/400 mg) FDC tablet administered orally once daily
Study NCT01965535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: RBV (200 mg tablets) administered orally in a divided daily dose based on weight (1000 mg per day for participants weighing \< 75 kg; 1200 mg per day for participants weighing ≥ 75 kg)
Study NCT01965535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match LDV/SOF
Description: Placebo to match LDV/SOF administered orally once daily
Study NCT01965535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match RBV
Description: Placebo to match RBV administered orally in a divided daily dose
Study NCT02491866 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: to develop and validate a Computerized Adaptative Testing
Description: * Elaboration of a pool of items, based on literature review and interview with patients.~* Selection of the most relevant items based on a qualitative approach using cognitive interview with patients.~* Calibration of the item bank : the psychometric properties of the item bank will be based on classical test and item response theories and approaches, including the evaluation of unidimensionality, item response theory model fitting, and analyses of differential item functioning.~* Metrological validation of the CAT.~* Analysis of the implementation of the CAT in clinical practice using interview with professionals and patients.
Study NCT02221336 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The MONARCA II system
Description: Daily electronic monitoring of subjective and objective smartphone measures including a feedback loop
Study NCT02221336 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Non-MONARCA II system
Description: Daily use of smartphone for normal communicative purposes. No self-monitoring in the MONARCA II system.
Study NCT01669122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine
Description: 4 mg nicotine lozenge experimental
Study NCT03451838 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Ultrasound will be done to every pregnant lady
Study NCT03451838 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HbA1c level in blood
Description: a blood sample will be taken to measure HbA1c level
Study NCT04331366 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GO2 PEEP MOUTHPIECE
Description: The GO2 PEEP MOUTHPIECE has a bidirectional valve that delivers PEEP with each breath. Participants will be provided a G02 PEEP MOUTHPIECE to use underneath the oxygen face mask and will be instructed to breathe slowly and deeply through the mouthpiece for 15 minutes total. Metrics for primary and secondary endpoints will be recorded immediately prior to use and then at 5, 10 and 15 minutes of use and then 15 minutes after cessation of use.